{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:29:34Z","timestamp":1790270974874,"version":"4.1.0"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian Dermatol Online J"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/idoj.idoj_474_18","type":"journal-article","created":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T02:51:33Z","timestamp":1559098293000},"page":"503","source":"Crossref","is-referenced-by-count":33,"title":["Oral tofacitinib: Contemporary appraisal of its role in dermatology"],"prefix":"10.4103","volume":"10","author":[{"given":"Parul","family":"Aggarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidharth","family":"Sonthalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2229-5178.259299-1","first-page":"745","volume-title":"Janus kinase inhibitors in dermatology: A systematic review","author":"Shreberk-Hassidim","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.259299-2","first-page":"476","volume-title":"Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature","author":"Samadi","year":"2017","journal-title":"J Dermatol Treat"},{"key":"key-10.4103\/2229-5178.259299-3","first-page":"7","volume-title":"Jakpot! New small molecules in autoimmune and inflammatory diseases","author":"Ghoreschi","year":"2014","journal-title":"Exp Dermatol"},{"key":"key-10.4103\/2229-5178.259299-4","first-page":"736","volume-title":"JAK inhibitors in dermatology: The promise of a new drug class","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.259299-5","first-page":"1096","volume-title":"Targeting JAK\/STAT signalling in inflammatory skin diseases with small molecule inhibitors","author":"Welsch","year":"2017","journal-title":"Eur J Immunol"},{"key":"key-10.4103\/2229-5178.259299-6","first-page":"405","volume-title":"VX-509 (decernotinib) is a potent and selective Janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease","author":"Mahajan","year":"201;","journal-title":"J Pharmacol Exp Ther"},{"key":"key-10.4103\/2229-5178.259299-7","unstructured":"US Food and Drug Administration. Xeljanz prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203214s018lbl.pdf. [Last cited on 2018 Nov 22]."},{"key":"key-10.4103\/2229-5178.259299-8","first-page":"1395","volume-title":"Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: A randomized controlled trial","author":"Bissonnette","year":"2015","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.259299-9","first-page":"552","volume-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: A phase 3 randomised non-inferiority trial","author":"Bachelez","year":"2015","journal-title":"Lancet Lond Engl"},{"key":"key-10.4103\/2229-5178.259299-10","first-page":"1753","volume-title":"Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: Patient-reported outcomes from a Phase 3 study","author":"Valenzuela","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/2229-5178.259299-11","first-page":"815","volume-title":"Long-term safety data for tofacitinib, an oral Janus kinase inhibitor, for the treatment for psoriasis","author":"Lloyd-Lavery","year":"2018","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.259299-12","unstructured":"Valenzuela F, Korman NJ, Bissonnette R, Bakos N, Tsai TF, Harper MK, et al. Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: Long-term safety and efficacy in an open-label extension study. Br J Dermatol, doi: 10.1111\/bjd. 16798."},{"key":"key-10.4103\/2229-5178.259299-13","first-page":"67","volume-title":"Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials","author":"Strober","year":"2019","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.259299-14","first-page":"1006","volume-title":"Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: A model-based meta-analysis","author":"Checchio","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"key-10.4103\/2229-5178.259299-15","first-page":"1537","volume-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2229-5178.259299-16","first-page":"1525","volume-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2229-5178.259299-17","first-page":"719","volume-title":"Tofacitinib for the treatment of psoriasis and psoriatic arthritis","author":"Berekmeri","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"key-10.4103\/2229-5178.259299-18","first-page":"2988","volume-title":"Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis","author":"Craiglow","year":"2014","journal-title":"J Invest Dermatol"},{"key":"key-10.4103\/2229-5178.259299-19","first-page":"e89776","volume-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","author":"Kennedy","year":"2016","journal-title":"JCI Insight"},{"key":"key-10.4103\/2229-5178.259299-20","first-page":"22","volume-title":"Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.259299-21","first-page":"1539","volume-title":"An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis","author":"Jabbari","year":"2018","journal-title":"J Invest Dermatol"},{"key":"key-10.4103\/2229-5178.259299-22","first-page":"733","volume-title":"Balance of tofacitinib efficacy and disease flare in the treatment of alopecia universalis: A case report and review of the literature","author":"Chiang","year":"2018","journal-title":"JAAD Case Rep"},{"key":"key-10.4103\/2229-5178.259299-23","first-page":"1","volume-title":"Janus kinase inhibitors for the treatment of severe alopecia areata: An open-label comparative study","author":"Almutairi","year":"2018","journal-title":"Dermatology"},{"key":"key-10.4103\/2229-5178.259299-24","first-page":"41","volume-title":"Comparison of the treatment outcome of oral tofacitinib with other conventional therapies in refractory alopecia totalis and universalis: A retrospective study","author":"Shin","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"key-10.4103\/2229-5178.259299-25","first-page":"819","volume-title":"Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib","author":"Lee","year":"2018","journal-title":"J Dermatol Treat"},{"key":"key-10.4103\/2229-5178.259299-26","first-page":"1110","volume-title":"Tofacitinib citrate for the treatment of vitiligo: A pathogenesis-directed therapy","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol"},{"key":"key-10.4103\/2229-5178.259299-27","first-page":"675","volume-title":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.259299-28","first-page":"370","volume-title":"Rapid repigmentation of vitiligo using tofacitinib plus low-dose, narrowband UV-B phototherapy","author":"Kim","year":"2018","journal-title":"JAMA Dermatol"},{"key":"key-10.4103\/2229-5178.259299-29","first-page":"395","volume-title":"Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate","author":"Levy","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.259299-30","first-page":"942","volume-title":"Oral tofacitinib: A promising treatment in atopic dermatitis, alopecia areata and vitiligo","author":"Vu","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"key-10.4103\/2229-5178.259299-31","first-page":"515","volume-title":"Simultaneous improvement of alopecia universalis and atopic dermatitis in a patient treated with a JAK inhibitor","author":"Morris","year":"2018","journal-title":"JAAD Case Rep"},{"key":"key-10.4103\/2229-5178.259299-32","first-page":"S1542","volume-title":"Tofacitinib for the treatment of pyoderma gangrenosum","author":"Kochar","year":"2018","journal-title":"Clin Gastroenterol Hepatol Epub"},{"key":"key-10.4103\/2229-5178.259299-33","first-page":"443","volume-title":"Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib","author":"Kim","year":"2018","journal-title":"JAAD Case Rep"},{"key":"key-10.4103\/2229-5178.259299-34","first-page":"e12656","volume-title":"Tofacitinib for the treatment of lichen planopilaris: A case series","author":"Yang","year":"2018","journal-title":"Dermatol Ther"},{"key":"key-10.4103\/2229-5178.259299-35","unstructured":"Hosking AM, Juhasz M, Mesinkovska NA. Topical Janus kinase inhibitors: A review of applications in dermatology. J Am Acad Dermatol 2018;79:535-44, doi: 10.1016\/j.jaad. 2018.04.018."},{"key":"key-10.4103\/2229-5178.259299-36","first-page":"777","volume-title":"Randomized pilot clinical trial of tofacitinib solution for plaque psoriasis: Challenges of the intra-subject study design","author":"Ports","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"key-10.4103\/2229-5178.259299-37","doi-asserted-by":"crossref","unstructured":"Liu LY, Craiglow BG, King BA. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients. J Am Acad Dermatol 2018;78:403-4.e1.","DOI":"10.1016\/j.jaad.2017.10.043"},{"key":"key-10.4103\/2229-5178.259299-38","first-page":"988","volume-title":"Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes","author":"Craiglow","year":"2018","journal-title":"JAAD Case Rep"},{"key":"key-10.4103\/2229-5178.259299-39","first-page":"1054","volume-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib","author":"Rothstein","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.259299-40","first-page":"167","volume-title":"Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata","author":"Bayart","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.259299-41","first-page":"755","volume-title":"Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis","author":"Clowse","year":"2016","journal-title":"Drug Saf"},{"key":"key-10.4103\/2229-5178.259299-42","first-page":"29","volume-title":"Tofacitinib for the treatment of alopecia areata and variants in adolescents","author":"Craiglow","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.259299-43","first-page":"568","volume-title":"Tofacitinib for the treatment of alopecia areata in preadolescent children","author":"Craiglow","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.259299-44","unstructured":"eMC. XELJANZ 5 mg film-coated tablets. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/2500\/smpc. [Last cited on 2018 Nov 25]."},{"key":"key-10.4103\/2229-5178.259299-45","first-page":"1872","volume-title":"Risk of tuberculosis in patients with chronic immunemediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies","author":"Souto","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"key-10.4103\/2229-5178.259299-46","first-page":"1133","volume-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","author":"Winthrop","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key-10.4103\/2229-5178.259299-47","first-page":"363","volume-title":"Malignancy risk and recurrence with psoriasis and its treatments: A concise update","author":"Geller","year":"2018","journal-title":"Am J Clin Dermatol"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:30:02Z","timestamp":1786714202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.IDOJ_474_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"alternative-id":["259299"],"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_474_18","relation":{},"ISSN":["2229-5178"],"issn-type":[{"value":"2229-5178","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}